David West, Procsia | theCUBE + NYSE Wired: MedTech Unplugged Series
Show Notes
In this episode of the MedTech Unplugged Series, David West, co-founder and CEO of Proscia, discusses the profound impact of AI and digital pathology on medical diagnostics with theCUBE's Dave Vellante. West outlines the journey of Proscia, detailing the development of its flagship product, Concentriq, a cloud-native SaaS solution aimed at revolutionizing traditional pathology workflows. He highlights the challenges faced by pathologists dealing with large datasets, often exceeding 100GB, and emphasizes the efficiency gains provided by AI in enhancing diagnostic accuracy and expediency. With significant funding of over $130 million and expanding use within the healthcare sector, Proscia is positioned at the nexus of AI, precision medicine, and value-based care. West also delves into regulatory challenges, pricing strategies, and the transformative potential of advanced AI technologies in healthcare.
Key Topics Covered:- Introduction to Proscia and the vision behind its founding in 2016.
- Overview of Concentriq and its role in transitioning pathology from microscope-based to data-driven diagnostics.
- Challenges faced by pathologists in handling large diagnostic image datasets.
- The efficiency and accuracy enhancements brought by AI in medical diagnostics.
- Navigating regulatory hurdles, including FDA and IVDR compliance.
- Diverse pricing strategies tailored to diagnostics and life sciences.
- Impact of large language models and multimodal AI on patient stratification and automation.
- Future outlook on AI in healthcare and its potential to reshape medical diagnostics.